Cylexin for Reduction of Reperfusion Injury in Infant Heart Surgery

Summary

We conducted a multicenter, randomized, placebo-controlled trial of Cylexin, an inhibitor of the attachment of white blood cells to the endothelium. Our study population was neonates and infants undergoing hypothermic cardiopulmonary bypass during surgical repair or palliation of congenital heart defects.

Timeline

Start

1997-12

Primary completion

—

Completion

2001-06

Drugs

Indications